| Patent application number | Description | Published |
|---|
| 20080241125 | MUC1-IKB KINASE COMPLEXES AND THEIR ACTIVITIES - The disclosure provides methods of identifying and making compounds and pharmaceutical compositions containing the compounds that inhibit the interaction between MUC1 and an IKK. The disclosure also provides in vivo and in vitro methods of inhibiting such an interaction. Also embraced by the disclosure are in vitro and in vivo methods of inhibiting the IKK/NF-κB pathway in cells expressing MUC1. The compounds, compositions, and methods of the disclosure are generally useful in the treatment of various cancers, inflammatory (e.g., autoimmune disorders), and transplant rejection. | 10-02-2008 |
| 20080286264 | Modulation of Muc1 Activity - The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either p53 or TBP. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of MUC1 by a cell. | 11-20-2008 |
| 20080311575 | Modulation of Muci-Dependent Anti-Estrogen Resistance - The present invention provides methods for identification and use of compounds that modulate the association of MUC1 with estrogen receptors and thereby antagonize MUC1-related resistance to anti-estrogen treatment. | 12-18-2008 |
| 20090087437 | METHODS AND COMPOSITIONS RELATING TO THE REGULATION OF APOPTOSIS BY MUC1 AND BH3-CONTAINING PROAPOPTOTIC PROTEINS - This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or immune cell growth. The invention provides methods of inhibiting interactions between MUC1 and BH3-containing proapoptotic proteins, methods of inhibiting MUC1 expression, and methods of promoting apoptosis. Also provided are screening methods for compounds that inhibit interactions between MUC1 and BH3-containing proapoptotic proteins and pharmaceutical compositions of the same. | 04-02-2009 |
| 20090092600 | METHODS AND COMPOSITIONS RELATING TO THE REGULATION OF MUC1 BY HSF1 AND STAT3 - This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of inhibiting interactions between MUC1 and a heat shock factor, method of inhibiting interactions between transcription factors and the MUC1 promoter, and methods of inhibiting expression. The invention also provides screening methods for identifying compounds that inhibit the aforementioned interactions. Pharmaceutical compositions containing the identified compounds can be useful in treating cancers and inflammatory conditions. | 04-09-2009 |
| 20090098054 | METHODS AND COMPOSITIONS RELATING TO PROMOTER REGULATION BY MUC1 AND KLF PROTEINS - This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of, and compositions useful for, inhibiting interactions between MUC1 and a kruppel-like factor (KLF), method of inhibiting interactions between a KLF protein and the p53 promoter, methods of inhibiting the interaction between MUC1 and the p53 promoter, methods of increasing p53 activity, and methods of increasing histone acetylation. The invention also provides screening methods for identifying compounds that inhibit the aforementioned interactions. Pharmaceutical compositions containing the identified compounds can be useful in treating cancers and inflammatory conditions. | 04-16-2009 |
| 20090136520 | MITOCHONDRIAL LOCALIZATION OF MUC1 - The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either or both of HSP70 and HSP90. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction. | 05-28-2009 |
| 20090232812 | MUC1 EXTRACELLULAR DOMAIN AND CANCER TREATMENT COMPOSITIONS AND METHODS DERIVED THEREFROM - The present invention provides compositions and methods for inhibiting the proliferation of cancer cells and for the treatment of tumors with antagonists of the binding of ligands to the extracellular domain of MUC1, such binding being related to an oncogenic function of MUC1. | 09-17-2009 |
| 20100098683 | MUC1 and Galectin-3 - The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and galectin-3. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of galectin-3 by a cell. | 04-22-2010 |
| 20100125055 | MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS INHIBITORS OF CANCER - The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo. | 05-20-2010 |
| 20110015138 | INHIBITION OF INFLAMMATION USING ANTAGONISTS OF MUC1 - The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling. | 01-20-2011 |
| 20110091375 | USE OF THE COMBINATION COMPRISING TEMOZOLOMIDE AND TNF-ALPHA FOR TREATING GLIOBLASTOMA - Disclosed are methods of synergistically inhibiting growth of a glioma cell comprising contacting the cell with temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Also disclosed are methods of synergistically inhibiting growth of a glioma in a human cancer patient comprising administering temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Pharmaceutical combinations and therapeutic combinations suitable for use in the methods of the invention are also disclosed. | 04-21-2011 |
